Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

被引：144
|
作者：
Chia, Puey Ling [1 ]
Mitchell, Paul [1 ]
Dobrovic, Alexander [2 ,3 ,4 ]
John, Thomas [1 ,2 ,4 ]
机构：
[1] Olivia Newton John Canc & Wellness Ctr, Dept Med Oncol, Heidelberg, Vic, Australia
[2] Austin Hlth, Ludwig Inst Canc Res, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia
[4] La Trobe Univ, Sch Canc Med, Bundoora, Vic 3086, Australia
来源：
CLINICAL EPIDEMIOLOGY | 2014年 / 6卷
关键词：
anaplastic lymphoma kinase (ALK); gene rearrangements; lung cancer; kinase inhibitors; lung adenocarcinoma; ANAPLASTIC LYMPHOMA KINASE; POLYMERASE CHAIN-REACTION; EML4-ALK FUSION VARIANTS; ACQUIRED-RESISTANCE; NEVER-SMOKERS; MOLECULAR CHARACTERIZATION; BRAF GENE; EGFR; MUTATIONS; IMMUNOHISTOCHEMISTRY;
D O I：
10.2147/CLEP.S69718
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.
引用
收藏
页码：423 / 432
页数：10
相关论文
共 50 条
  • [1] Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse
    Cortinovis, Diego
    Canova, Stefania
    Abbate, Maria I.
    Colonese, Francesca
    Cogliati, Viola
    Bidoli, Paolo
    FUTURE ONCOLOGY, 2018, 14 (22) : 2303 - 2317
  • [2] ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non-Small-Cell Lung Cancer?
    Toyokawa, Gouji
    Seto, Takashi
    CLINICAL LUNG CANCER, 2014, 15 (05) : 313 - 319
  • [3] Alectinib for treatment of ALK-positive non-small-cell lung cancer
    Avrillon, Virginie
    Perol, Maurice
    FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
  • [4] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
  • [5] Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
    Kanaan, Zeyad
    Kloecker, Goetz H.
    Paintal, Ajit
    Perez, Cesar A.
    ONCOTARGETS AND THERAPY, 2015, 8 : 885 - 892
  • [6] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [7] The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer
    Amanam, Idoroenyi
    Gupta, Rohan
    Mambetsariev, Isa
    Salgia, Ravi
    FUTURE ONCOLOGY, 2018, 14 (19) : 1897 - 1908
  • [8] Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements - comparison of multiple immunohistochemical methods
    Zwaenepoel, Karen
    Van Dongen, Amber
    Lambin, Suzan
    Weyn, Christine
    Pauwels, Patrick
    HISTOPATHOLOGY, 2014, 65 (04) : 539 - 548
  • [9] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [10] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
12345